Literature DB >> 23093650

Novel insights into immune and inflammatory responses to respiratory viruses.

Jürgen Schwarze1, Karen J Mackenzie.   

Abstract

Viral lower respiratory tract infection (LRTI) can lead to severe disease at all ages, but with the exception of influenza vaccination, prevention is not available for most respiratory viruses, hence, effective, disease-limiting therapy is urgently required. To enable the development of novel effective therapeutic approaches, we need to improve understanding of the pathological mechanisms of viral LRTI. Here, we will discuss recently gained new insight into early, innate immune and inflammatory responses to respiratory viruses by airway epithelial cells and mucosal immune cells. Following virus recognition, these cells generate a range of mediators, including innate interferons, proinflammatory cytokines, and growth and differentiation factors which have pivotal roles in effective virus control, and the development of inflammation and disease in viral LRTI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23093650     DOI: 10.1136/thoraxjnl-2012-202291

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  c-Jun N-terminal kinase and Akt signalling pathways regulating tumour necrosis factor-α-induced interleukin-32 expression in human lung fibroblasts: implications in airway inflammation.

Authors:  Dagen Li; Dapeng Chen; Xuemei Zhang; Hong Wang; Zixin Song; Wenchun Xu; Yujuan He; Yibing Yin; Ju Cao
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

2.  Critical Adverse Impact of IL-6 in Acute Pneumovirus Infection.

Authors:  Caroline M Percopo; Michelle Ma; Todd A Brenner; Julia O Krumholz; Timothy J Break; Karen Laky; Helene F Rosenberg
Journal:  J Immunol       Date:  2018-12-21       Impact factor: 5.422

3.  Administration of immunobiotic Lactobacillus plantarum delays but does not prevent lethal pneumovirus infection in Rag1-/- mice.

Authors:  Caroline M Percopo; Michelle Ma; Helene F Rosenberg
Journal:  J Leukoc Biol       Date:  2017-06-15       Impact factor: 4.962

4.  Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: a randomized controlled trial.

Authors:  S V Gerasimov; V A Ivantsiv; L M Bobryk; O O Tsitsura; L P Dedyshin; N V Guta; B V Yandyo
Journal:  Eur J Clin Nutr       Date:  2015-10-14       Impact factor: 4.016

5.  Immunobiotic Lactobacillus administered post-exposure averts the lethal sequelae of respiratory virus infection.

Authors:  Caroline M Percopo; Tyler A Rice; Todd A Brenner; Kimberly D Dyer; Janice L Luo; Kishore Kanakabandi; Daniel E Sturdevant; Stephen F Porcella; Joseph B Domachowske; Jesse D Keicher; Helene F Rosenberg
Journal:  Antiviral Res       Date:  2015-07-02       Impact factor: 5.970

6.  Pidotimod: the state of art.

Authors:  Beatrice E Ferrario; Silvia Garuti; Fulvio Braido; Giorgio W Canonica
Journal:  Clin Mol Allergy       Date:  2015-05-21

7.  Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019.

Authors:  Saravanan Subramaniam; Wolfram Ruf; Markus Bosmann
Journal:  Br J Pharmacol       Date:  2021-07-07       Impact factor: 8.739

8.  Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases.

Authors:  Sulagna Bhattacharya; Sakshi Agarwal; Nishith M Shrimali; Prasenjit Guchhait
Journal:  Mol Aspects Med       Date:  2021-07-19

Review 9.  Cytokine production and signaling pathways in respiratory virus infection.

Authors:  Hirokazu Kimura; Masakazu Yoshizumi; Haruyuki Ishii; Kazunori Oishi; Akihide Ryo
Journal:  Front Microbiol       Date:  2013-09-17       Impact factor: 5.640

Review 10.  Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis.

Authors:  Ralph A Tripp
Journal:  Immune Netw       Date:  2013-10-26       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.